FDA Issues Public Warning Against Purchasing Weight-Loss Supplements

FDA Issues Public Warning Against Purchasing Weight-Loss Supplements
September 15, 2014

The U.S. Food and Drug Administration (FDA) has issued warnings advising the public to avoid purchasing weight-loss supplements that contain hidden ingredients.

Specifically, the FDA issued warnings this week against Mezo, LX1 and Best Line Suplemento Alimenticio, which were sold online and in some retail stores.

Mezo and Best Line Suplemento Alimenticio Capsules

In a recent analysis, the FDA found that both Mezo and Best Line Suplemento Alimenticio capsules contain benzylsibutramine, a substance structurally similar to sibutramine. Sibutramine is a controlled substance that was removed from the market in October 2010 for safety reasons.

Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. This product may also interact, in life-threatening ways, with other medications a consumer may be taking.

LX1

AnFDA analysis confirmed that LX1 contains undeclared DMAA, also known as 1,3-dimethylamylamine, methylhexanamine or geranium extract.

Ingestion of DMAA can elevate blood pressure and could lead to cardiovascular problems, including heart attack, shortness of breath and tightening of the chest.

Reporting

The FDA is asking that consumers who purchased these products discard them immediately.

Health care professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.